STAR IN THE NEWS​

Press Releases

Star Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12

  • Purohit Navigation
  • January 5, 2026
SOUTH SAN FRANCISCO, CA, January 5, 2026 – Star Therapeutics, a late clinical-stage biotechnology company discovering and developing best-in-class antibodies for bleeding disorders and other diseases, today announced that Adam Rosenthal, Ph.D., CEO and Founder, will present at the 44th Annual...

Star Therapeutics Presents Interim Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease, Demonstrating Substantial Bleed Reductions in All Patients, at ASH Annual Meeting

  • Purohit Navigation
  • December 6, 2025
SOUTH SAN FRANCISCO, CA, December 6, 2025 – Star Therapeutics, a late clinical-stage biotechnology company discovering and developing best-in-class antibodies for bleeding disorders and other diseases, today announced interim data from its ongoing Phase 1/2 multidose...

Star Therapeutics to Present Interim Data from Phase 1/2 Multidose Study of VGA039 in von Willebrand disease at ASH Annual Meeting

  • Purohit Navigation
  • November 3, 2025
SOUTH SAN FRANCISCO, CA, November 3, 2025 – Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies for bleeding disorders and other diseases, today...

Star Therapeutics Announces Oversubscribed $125 Million Series D Financing

  • Purohit Navigation
  • September 30, 2025
SOUTH SAN FRANCISCO, CA, September 30, 2025 – Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies for bleeding disorders and other diseases, today announced an oversubscribed $125 million Series D financing.

Star Therapeutics Receives FDA Fast Track Designation for VGA039 in Von Willebrand Disease (VWD)

  • Purohit Navigation
  • January 6, 2025
SOUTH SAN FRANCISCO, CA, January 6, 2025 – Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies...

Star Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

  • Purohit Navigation
  • January 2, 2025
SOUTH SAN FRANCISCO, CA, January 2, 2025 – Star Therapeutics, a clinical stage biotechnology company.

Star Therapeutics Presents Interim Clinical Data for VGA039 in Patients with Von Willebrand Disease (VWD) at ASH 2024

  • Purohit Navigation
  • December 9, 2024
SOUTH SAN FRANCISCO, CA, December 9, 2024 – Star Therapeutics, a clinical stage biotechnology company.

Star Therapeutics Presents Clinical Data for VGA039, a Subcutaneous Therapy for the Treatment of Von Willebrand Disease (VWD)

  • Purohit Navigation
  • June 26, 2024
SOUTH SAN FRANCISCO, CA, June 26, 2024 – Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies...

Star Therapeutics Appoints Scott Robertson, MBA, as Chief Business Officer and Chief Financial Officer

  • Purohit Navigation
  • January 3, 2024
SOUTH SAN FRANCISCO, CA, January 3, 2024 – Star Therapeutics, a biotechnology company interrogating novel biology to develop life-changing therapies...

Star Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

  • Purohit Navigation
  • January 2, 2024
SOUTH SAN FRANCISCO, CA, January 2, 2024 – Star Therapeutics, a biotechnology company interrogating novel biology to develop life-changing therapies...

News Coverage

Star Therapeutics details early data for blood disorder shot, weighs IPO potential

  • Lei Lei Wu, Endpoints News
  • December 7, 2025
ORLANDO, Fla. — Star Therapeutics said its once-a-month injection for von Willebrand disease substantially cut bleeding rates in a preliminary study, and is thinking about the next moves to complete a larger trial and eventually get the drug to patients. The trial data released Saturday looked at eight patients, and showed that treatment with Star’s shot decreased bleeds by a median of 81%...

ASH: Star antibody sparkles in preview of potential phase 3 bleeding disease success

  • Darren Incorvaia, Fierce Biotech
  • December 7, 2025
ORLANDO, Fla. — With dosing underway in a pivotal phase 3 trial, Star Therapeutics is illuminating the clinical potential of its anti-bleeding antibody VGA039. In a phase 1/2 trial in von Willebrand disease (VWD), the molecule substantially reduced bleeding in eight patients. “We're seeing significant reductions in bleeds across all types of VWD and all types of bleeds,” Star founder...

ASH 2025: Von Willebrand disease is the most common bleeding disorder, though many people have never heard of it. Star Therapeutics is working on a solution that is already in phase 3

  • BiotechTV
  • December 6, 2025
Founder and CEO Adam Rosenthal describes the unmet need for patients with this condition, and walks us through VGA039, a protein S modulator.

Star gets $125M Series D as it begins Phase 3 in bleeding disorders

  • Kyle LaHucik, Endpoints News
  • September 30, 2025
Star Therapeutics patched together a $125 million Series D in what it thinks is pharma’s next big therapeutic category. The South San Francisco startup expects the funds to add a few years of runway and get its sole clinical-stage drug most of the way through a Phase 3 trial in von Willebrand disease while also expanding into other disorders, CEO Adam Rosenthal told Endpoints News...

Star raises another $125M for its blood disease drug

  • Gwendolyn Wu, BioPharma Dive
  • September 30, 2025
The biotech began Phase 3 testing of an experimental medicine for Von Willebrand disease in early September. Star Therapeutics has raised $125 million in new venture funding that will help propel its experimental blood disease drug through late-stage testing. Initially formed as a “hub-and-spoke” biotech intending to build single-drug offshoots, Star is now primarily focused on a singular program for...

Star Therapeutics collects shiny $125M funding boost to push bleeding disorder prospect into orbit

  • Zoey Becker, Fierce Biotech
  • September 30, 2025
A hefty $125 million in new financing has been written in the stars for Star Therapeutics through an oversubscribed series D funding round. The series D was co-led by Sanofi Ventures and Viking Global Investors, with support from over a dozen existing investors including Sofinnova, Blue Owl Capital and RA Capital Management. New investors such as Janus Henderson...

Breaking new ground in von Willebrand disease treatment

  • Jules Adam, Labiotech
  • January 9, 2025
Earlier this week, Star Therapeutics’ von Willebrand disease candidate – VGA039 – was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). While it is the most common inherited bleeding disorder and affects about 1% of the population, you don’t hear about von Willebrand disease every day. With Star Therapeutics’ candidate getting some recognition from the FDA...

Presentations

A PHASE IA STUDY OF VGA039, A PROTEIN S–TARGETING MONOCLONAL ANTIBODY, IN INDIVIDUALS WITH VON WILLEBRAND DISEASE DEMONSTRATES CONCENTRATION-DEPENDENT INCREASES IN THROMBIN GENERATION FOR REDUCING BLEEDING

  • Purohit Navigation
  • December 9, 2024
ASH 2024 ABSTRACT #3981

DIAGNOSIS AND DISEASE BURDEN OF VON WILLEBRAND DISEASE IN A LARGE US POPULATION–BASED DATASET

  • Purohit Navigation
  • December 9, 2024
ASH 2024 ABSTRACT #3980

DISPARITIES IN REAL-WORLD TREATMENT PATTERNS AMONG PATIENTS WITH VON WILLEBRAND DISEASE IN A LARGE US POPULATION-BASED DATASET

  • Purohit Navigation
  • December 9, 2024
ASH 2024 ABSTRACT #3978

Factor VIII Coagulant Activity (FVIII:C) as an Independent Predictor of Bleeding across Different Subtypes of Von Willebrand Disease (VWD)

  • Purohit Navigation
  • December 9, 2024
ASH 2024 ABSTRACT #3982